Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination
Across three layers of evidence, this study showed that heterologous vaccination provides longer-lasting immunity than homologous doses, regardless of prior natural infection.
Authors
- Ammar H. Alsughayir (ORCID: https://orcid.org/0000-0003-3606-0542)
- Alyazeed S. Alsaif
- Haitham S. Alkadi (ORCID: https://orcid.org/0000-0002-8071-9837)
- Wael Alturaiki (ORCID: https://orcid.org/0000-0002-6947-7582)
- Halah Z. AlRawi (ORCID: https://orcid.org/0000-0001-6761-9519)
- Maaweya Awadalla (ORCID: https://orcid.org/0000-0002-1270-2216)
- Bandar Alosaimi (ORCID: https://orcid.org/0000-0003-4719-2655)
- Ayman Mubarak (ORCID: https://orcid.org/0000-0003-4948-5574)
- Ahmed Alyami (ORCID: https://orcid.org/0000-0003-3679-2831)
- Fawziya Barnawi
- Rahaf A. Henawi
Institutions
- Majmaah University (SA)
- King Fahd Medical City (SA)
- King Saud University (SA)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-01-22
- DOI
- https://doi.org/10.3389/fimmu.2025.1526444
- Citations
- 6
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 8.38
Funders
- King Fahad Medical City